LuciVemu (Vemurafenib) 240 mg 56 tab (Zelboraf)

LuciVemu (Vemurafenib) 240 mg

General Information

• Brand name: LuciVemu 240 mg
• Active ingredient: Vemurafenib
• Dosage form: Film-coated tablets, 240 mg each
• Manufacturer: Lucius Pharmaceuticals / LuciVemu (India)
• Therapeutic class: BRAF kinase inhibitor (anti-cancer drug)

Mechanism of Action

Vemurafenib is a selective inhibitor of the mutated BRAF V600E kinase, which abnormally activates the MAPK/ERK signaling pathway, leading to uncontrolled cell growth in melanoma.
By blocking this pathway, LuciVemu halts tumor proliferation and triggers apoptosis (programmed cell death).

As a result, it helps slow down or stop tumor progression in patients carrying the BRAF V600E mutation.

Indications

LuciVemu 240 mg is indicated for:

• Unresectable or metastatic melanoma with a confirmed BRAF V600E mutation;
• Erdheim-Chester disease with BRAF V600 mutation.

BRAF mutation testing must be performed before treatment initiation.

Dosage and Administration

• Recommended adult dose: 960 mg twice daily (4 × 240 mg tablets in the morning and 4 in the evening).
• Tablets should be swallowed whole with water, with or without food.
• Dose reductions may be required in case of adverse reactions.
• Duration of therapy depends on clinical response and tolerance.

Contraindications

• Hypersensitivity to vemurafenib or excipients;
• Absence of BRAF V600E mutation;
• Pregnancy or breastfeeding (use only if benefits outweigh risks);
• Severe hepatic or renal impairment (use with caution).

Adverse Reactions

Common:

• Rash, itching, photosensitivity;
• Fatigue, arthralgia, myalgia;
• Nausea, diarrhea, loss of appetite;
• Elevated liver enzymes.

Serious:

• Cutaneous squamous cell carcinoma (cuSCC);
• QT interval prolongation;
• Severe skin reactions (Stevens-Johnson syndrome).

Immediate medical attention is required if serious side effects occur.

Precautions

• BRAF V600E mutation must be confirmed before starting treatment.
• Regular monitoring of ECG, liver function, skin and eye health is recommended.
• Avoid direct sunlight and use sunscreen during therapy.

Packaging and Storage

• Tablets 240 mg, in packs of 30, 60, or 120 tablets.
• Store at 15–25 °C, in a dry place away from light and moisture.
• Keep out of reach of children.
• Shelf life: 24 months.

Note

LuciVemu 240 mg is a prescription-only medicine.
Treatment must be initiated and supervised by an oncologist experienced in targeted therapy.
Self-medication is not recommended.

Contact us in Telegram